Alcon Names Stephen S. Lane, MD, as Chief Medical Officer

May 12, 2017: By Joan McKenna
Stephen Lane, MD

Stephen Lane, MD

Ophthalmologist Stephen S. Lane, MD, will join Alcon as chief medical officer and global head of clinical strategy, as of June 1, the company announced May 8.

Lane specializes in cataract surgery, cornea/external diseases, anterior segment surgery, LASIK, and refractive surgery.

He is a founding partner of Associated Eye Care of Stillwater, Minnesota, and was president of the American Society of Cataract and Refractive Surgery (ASCRS) from 2003 to 2004.

Alcon, the Fort Worth, Texas-based eye care division of Switzerland’s Novartis, said Lane’s experience in ophthalmic surgery, contact lens and intraocular lens development, clinical trial design and execution, and the regulatory process should complement Alcon’s strategy.

Lane succeeds Peter Richardson, MD, in the role.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022